Amonafide
Amonafide
Amonafide, bearing the original designation AS1413, is an investigational drug undergoing study for its potential use in oncology. Recognized by trade names such as Quinamed and Xanafide, Amonafide emerges from the novel category of chemotherapy agents referred to as Naphthalimides. These agents function by inhibiting the topoisomerase enzyme and also intercalating DNA, leading to disruption in the replication processes of cancer cells.
Contents
- 1 Chemical Classification
- 2 Mechanism of Action
- 3 Development and Clinical Trials
- 4 FDA Fast Track Status
- 5 Potential Therapeutic Uses
- 6 See Also
- 7 References
Chemical Classification
Amonafide is a representative member of the Naphthalimides family of chemotherapeutic agents.
Mechanism of Action
At its core, Amonafide functions as a:
- Topoisomerase inhibitor: By inhibiting the action of topoisomerase, Amonafide stalls the DNA replication process, halting the rapid division of cancer cells.
- DNA intercalator: The drug wedges itself between the base pairs in the DNA structure, further hampering the DNA replication and transcription processes.
Development and Clinical Trials
Antisoma, a renowned pharmaceutical company, is at the helm of developing Amonafide as a potential anti-cancer therapy. Key milestones in its clinical development include:
- 2008: The drug reached Phase III of clinical trials.
- March 2010: Initiation of Phase III trial targeting secondary Acute Myeloid Leukaemia (AML).
- June 2010: The U.S. Food and Drug Administration (FDA) conferred a Fast Track Status on Amonafide for the treatment of Secondary Acute Myeloid Leukaemia (AML).
FDA Fast Track Status
In June 2010, the FDA accorded Amonafide with a Fast Track Status. This designation is reserved for medications with the potential to address unmet medical needs, facilitating a more streamlined review process for the drug.
Potential Therapeutic Uses
While the primary focus is on harnessing Amonafide's properties to combat secondary AML, ongoing research is expected to uncover its efficacy in treating other cancer forms as well.
See Also
External links
- Amonafide entry in the public domain NCI Dictionary of Cancer Terms
- Clinical trials of amonafide at ClinicalTrials.gov
This article is a medical stub. You can help WikiMD by expanding it! | |
---|---|
This article incorporates public domain material from the U.S. National Cancer Institute document "Dictionary of Cancer Terms".
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD